RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCIE SCOPUS

      Value of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Previous Excisional Biopsy

      한글로보기

      https://www.riss.kr/link?id=A104425718

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Purpose: Sentinel lymph node biopsy (SLNB) in breast cancer patients with clinically negative axilla will ensure axillary dissection only for cases with lymph node metastasis and provide information about pathologic staging as accurate as the axillary dissection. It was shown that SLNB could be successfully performed regardless of the type of biopsy. The aim of this study was to investigate the feasibility of SLNB after excisional biopsy. Methods:One hundred patients diagnosed with excisional biopsy or guide wire-localization and operated on with SLNB between February 2007 and March 2009 were retrospectively analyzed. SLNB was performed with 10 cc of 1% methylene blue alone or both methylene blue and 1 mCi of Tc-99m nanocolloid combination. Age, tumor localization and size, length of the biopsy incision, size of the biopsy specimen, multifocality, lymphovascular invasion, tumor grade, staining with methylene blue, localization, number and metastatic status of the lymph nodes stained, and success rate with a gamma probe were evaluated. Results: Sentinel lymph node (SLN) could not be identified in 9 (16.9%) of patients in the methylene blue group (n=53). In the combination group (n=47), SLN could not be identified in one patient. Of 32 patients with negative SLNB, metastatic involvement was found to be present in 5 patients after axillary lymph node dissection (false negatives). The average numbers of SLNs found in the methylene blue group and combination group were 1.4 and 1.6, respectively. SLN detection and false negative rates in the methylene blue group were 83% and 15.7%, respectively. The rates for the combination group were 98% and 6.4%, respectively. None of the parameters related to patient, tumor or process were found to affect detection rates of SLN. Conclusion: Only SLNB using a combination method is a safe and reliable technique for breast cancer patients diagnosed with excisional biopsy.
      번역하기

      Purpose: Sentinel lymph node biopsy (SLNB) in breast cancer patients with clinically negative axilla will ensure axillary dissection only for cases with lymph node metastasis and provide information about pathologic staging as accurate as the axillary...

      Purpose: Sentinel lymph node biopsy (SLNB) in breast cancer patients with clinically negative axilla will ensure axillary dissection only for cases with lymph node metastasis and provide information about pathologic staging as accurate as the axillary dissection. It was shown that SLNB could be successfully performed regardless of the type of biopsy. The aim of this study was to investigate the feasibility of SLNB after excisional biopsy. Methods:One hundred patients diagnosed with excisional biopsy or guide wire-localization and operated on with SLNB between February 2007 and March 2009 were retrospectively analyzed. SLNB was performed with 10 cc of 1% methylene blue alone or both methylene blue and 1 mCi of Tc-99m nanocolloid combination. Age, tumor localization and size, length of the biopsy incision, size of the biopsy specimen, multifocality, lymphovascular invasion, tumor grade, staining with methylene blue, localization, number and metastatic status of the lymph nodes stained, and success rate with a gamma probe were evaluated. Results: Sentinel lymph node (SLN) could not be identified in 9 (16.9%) of patients in the methylene blue group (n=53). In the combination group (n=47), SLN could not be identified in one patient. Of 32 patients with negative SLNB, metastatic involvement was found to be present in 5 patients after axillary lymph node dissection (false negatives). The average numbers of SLNs found in the methylene blue group and combination group were 1.4 and 1.6, respectively. SLN detection and false negative rates in the methylene blue group were 83% and 15.7%, respectively. The rates for the combination group were 98% and 6.4%, respectively. None of the parameters related to patient, tumor or process were found to affect detection rates of SLN. Conclusion: Only SLNB using a combination method is a safe and reliable technique for breast cancer patients diagnosed with excisional biopsy.

      더보기

      참고문헌 (Reference)

      1 Wong SL, "The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy" 9 : 272-277, 2002

      2 Krag DN, "Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically nodenegative breast cancer: results from the NSABP B-32 randomised phase III trial" 8 : 881-888, 2007

      3 Ruano R, "Staging the axilla with selective sentinel node biopsy in patients with previous excision of non-palpable and palpable breast cancer" 35 : 1299-1304, 2008

      4 Nos C, "Sentinel lymph node detection for breast cancer: which patients are best suited for the patent blue dye only method of identification?" 8 : 438-443, 2001

      5 O’Hea BJ, "Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center" 186 : 423-427, 1998

      6 McMasters KM, "Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used" 18 : 2560-2566, 2000

      7 Hung WK, "Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer" 92 : 1494-1497, 2005

      8 Rutgers EJ, "Quality control in the locoregional treatment of breast cancer" 37 : 447-453, 2001

      9 Tafra L, "Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye" 233 : 51-59, 2001

      10 Chen SL, "Lymphatic mapping and sentinel node analysis: current concepts and applications" 56 : 292-309, 2006

      1 Wong SL, "The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy" 9 : 272-277, 2002

      2 Krag DN, "Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically nodenegative breast cancer: results from the NSABP B-32 randomised phase III trial" 8 : 881-888, 2007

      3 Ruano R, "Staging the axilla with selective sentinel node biopsy in patients with previous excision of non-palpable and palpable breast cancer" 35 : 1299-1304, 2008

      4 Nos C, "Sentinel lymph node detection for breast cancer: which patients are best suited for the patent blue dye only method of identification?" 8 : 438-443, 2001

      5 O’Hea BJ, "Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center" 186 : 423-427, 1998

      6 McMasters KM, "Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used" 18 : 2560-2566, 2000

      7 Hung WK, "Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer" 92 : 1494-1497, 2005

      8 Rutgers EJ, "Quality control in the locoregional treatment of breast cancer" 37 : 447-453, 2001

      9 Tafra L, "Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye" 233 : 51-59, 2001

      10 Chen SL, "Lymphatic mapping and sentinel node analysis: current concepts and applications" 56 : 292-309, 2006

      11 Feldman SM, "Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy" 188 : 248-254, 1999

      12 Estourgie SH, "Excision biopsy of breast lesions changes the pattern of lymphatic drainage" 94 : 1088-1091, 2007

      13 Cody HS 3rd, "Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures" 8 : 13-19, 2001

      14 Varghese P, "Carpenter R. Methylene blue dye--a safe and effective alternative for sentinel lymph node localization" 14 : 61-67, 2008

      15 Greenlee RT, "Cancer statistics, 2000" 50 : 7-33, 2000

      16 Sakorafas GH, "Breast cancer surgery: historical evolution, current status and future perspectives" 40 : 5-18, 2001

      17 Greco M, "Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis" 232 : 1-7, 2000

      18 Chagpar AB, "Biopsy type does not influence sentinel lymph node status" 190 : 551-556, 2005

      19 Haigh PI, "Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer" 7 : 21-27, 2000

      20 Derossis AM, "A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer" 193 : 473-478, 2001

      21 Blessing WD, "A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping" 184 : 341-345, 2002

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-04-06 학술지명변경 외국어명 : Journal of Korean Breast Cancer -> Journal of Breast Cancer KCI등재
      2011-03-23 학술지명변경 외국어명 : Journal of Korean Breast Cancer -> 미등록 KCI등재
      2011-03-04 학술지명변경 한글명 : 한국유방암학회지 -> Journal of Breast Cancer KCI등재
      2011-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2010-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2008-01-01 평가 SCIE 등재 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 1.99 0.19 1.31
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.96 0.77 0.448 0.06
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼